Literature DB >> 20437578

An ethical hierarchy for decision making during medical emergencies.

Patrick D Lyden1, Brett C Meyer, Thomas M Hemmen, Karen S Rapp.   

Abstract

Evidence from well-designed clinical trials may guide clinicians, reduce regional variation, and lead to improved outcomes. Many physicians choose to ignore evidence-based practice guidelines. Using unproven therapies outside of a randomized trial slows recruitment in clinical trials that could yield information on clinical and economic efficacy. Using acute stroke therapy as an illustration, we present an ethical hierarchy for therapeutic decision making during medical emergencies. First, physicians should offer standard care. If no standard care option exists, the physician should consider enrollment in a randomized clinical trial. If no trial is appropriate, the physician should consider a nonrandomized registry, or consensus-based guidelines. Finally, only after considering the first 3 options, the physician should use best judgment based on previous personal experience and any published case series or anecdotes. Given the paucity of quality randomized clinical trial data for most medical decisions, the "best judgment" option will be used most frequently. Nevertheless, such a hierarchy is needed because of the limited time during medical emergencies for consideration of general principles of clinical decision making. There should be general agreement in advance as to the hierarchy to follow in selecting treatment for critically ill patients. Were more clinicians to follow this hierarchy, and choose to participate in clinical trials, the generation of new knowledge would accelerate, yielding rigorous data supporting or refuting the efficacy and safety of new interventions more quickly, thus benefiting far more patients over time.

Entities:  

Mesh:

Year:  2010        PMID: 20437578      PMCID: PMC2875330          DOI: 10.1002/ana.21997

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  25 in total

1.  Current methods of the US Preventive Services Task Force: a review of the process.

Authors:  R P Harris; M Helfand; S H Woolf; K N Lohr; C D Mulrow; S M Teutsch; D Atkins
Journal:  Am J Prev Med       Date:  2001-04       Impact factor: 5.043

Review 2.  The ambiguity and the exigency: clarifying 'standard of care' arguments in international research.

Authors:  A J London
Journal:  J Med Philos       Date:  2000-08

Review 3.  Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials.

Authors:  Gordon C S Smith; Jill P Pell
Journal:  BMJ       Date:  2003-12-20

4.  Financial conflicts of interest in physicians' relationships with the pharmaceutical industry--self-regulation in the shadow of federal prosecution.

Authors:  David M Studdert; Michelle M Mello; Troyen A Brennan
Journal:  N Engl J Med       Date:  2004-10-28       Impact factor: 91.245

Review 5.  From randomized trials to registry studies: translating data into clinical information.

Authors:  Morgan L Brown; Bernard J Gersh; David R Holmes; Kent R Bailey; Thoralf M Sundt
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2008-08-05

6.  Adverse event detection in drug development: recommendations and obligations beyond phase 3.

Authors:  Jesse A Berlin; Susan C Glasser; Susan S Ellenberg
Journal:  Am J Public Health       Date:  2008-06-12       Impact factor: 9.308

Review 7.  Decision making in medicine and health care.

Authors:  Robert M Kaplan; Dominick L Frosch
Journal:  Annu Rev Clin Psychol       Date:  2005       Impact factor: 18.561

8.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.

Authors:  Werner Hacke; Markku Kaste; Erich Bluhmki; Miroslav Brozman; Antoni Dávalos; Donata Guidetti; Vincent Larrue; Kennedy R Lees; Zakaria Medeghri; Thomas Machnig; Dietmar Schneider; Rüdiger von Kummer; Nils Wahlgren; Danilo Toni
Journal:  N Engl J Med       Date:  2008-09-25       Impact factor: 91.245

9.  Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials.

Authors:  Werner Hacke; Geoffrey Donnan; Cesare Fieschi; Markku Kaste; Rüdiger von Kummer; Joseph P Broderick; Thomas Brott; Michael Frankel; James C Grotta; E Clarke Haley; Thomas Kwiatkowski; Steven R Levine; Chris Lewandowski; Mei Lu; Patrick Lyden; John R Marler; Suresh Patel; Barbara C Tilley; Gregory Albers; Erich Bluhmki; Manfred Wilhelm; Scott Hamilton
Journal:  Lancet       Date:  2004-03-06       Impact factor: 79.321

Review 10.  Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate.

Authors:  Gunn Elisabeth Vist; Dianne Bryant; Lyndsay Somerville; Trevor Birminghem; Andrew D Oxman
Journal:  Cochrane Database Syst Rev       Date:  2008-07-16
View more
  5 in total

1.  Selecting Patients for Intra-Arterial Therapy in the Context of a Clinical Trial for Neuroprotection.

Authors:  Patrick Lyden; Sara Weymer; Chris Coffey; Merit Cudkowicz; Samantha Berg; Sarah O'Brien; Marc Fisher; E Clarke Haley; Pooja Khatri; Jeff Saver; Steven Levine; Howard Levy; Marilyn Rymer; Lawrence Wechsler; Ashutosh Jadhav; Elizabeth McNeil; Salina Waddy; Kent Pryor
Journal:  Stroke       Date:  2016-11-01       Impact factor: 7.914

2.  When less is more (brain)-comment on "Rivaroxaban plasma levels in acute ischemic stroke and intracerebral hemorrhage".

Authors:  Patrick D Lyden
Journal:  Ann Neurol       Date:  2018-03-03       Impact factor: 10.422

3.  Stroke treatment academic industry roundtable: research priorities in the assessment of neurothrombectomy devices.

Authors:  Jeffrey L Saver; Tudor G Jovin; Wade S Smith; Gregory W Albers; Jean-Claude Baron; Johannes Boltze; Joseph P Broderick; Lisa A Davis; Andrew M Demchuk; Salvatore DeSena; Jens Fiehler; Philip B Gorelick; Werner Hacke; Bill Holt; Reza Jahan; Hui Jing; Pooja Khatri; Chelsea S Kidwell; Kennedy R Lees; Michael H Lev; David S Liebeskind; Marie Luby; Patrick Lyden; J Thomas Megerian; J Mocco; Keith W Muir; Howard A Rowley; Richard M Ruedy; Sean I Savitz; Vitas J Sipelis; Samuel K Shimp; Lawrence R Wechsler; Max Wintermark; Ona Wu; Dileep R Yavagal; Albert J Yoo
Journal:  Stroke       Date:  2013-11-05       Impact factor: 7.914

4.  Are randomized, blind clinical trials enough to guide individualized decisions for patients with neurologic diseases?

Authors:  Yazan J Alderazi; Roberto Bomprezzi
Journal:  Neurol Clin Pract       Date:  2014-08

5.  Prototyping a precision oncology 3.0 rapid learning platform.

Authors:  Connor Sweetnam; Simone Mocellin; Michael Krauthammer; Nathaniel Knopf; Robert Baertsch; Jeff Shrager
Journal:  BMC Bioinformatics       Date:  2018-09-26       Impact factor: 3.169

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.